Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...
The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...
A recent study found that glucagon-like peptide-1 receptor (GLP-1) agonists like semaglutide and liraglutide are effective in ...
In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay ...
However, authors caution there is little high-quality evidence. (HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a ...
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...